Li Jiaosheng, Zhang Xiufen, Liu You, Li Qinhua, Guo Yifan, Yu Haotian
The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510168, China.
Department of Obstetrics and Gynecology, Hainan Hospital of PLA General Hospital, Sanya 572013, China.
Gynecol Oncol Rep. 2022 Sep 6;43:101066. doi: 10.1016/j.gore.2022.101066. eCollection 2022 Oct.
Diffuse large B-cell lymphoma (DLBCL) is a rare disease with a crude annual incidence rate of 3.8 cases per 100,000 people. Besides, primary cervical lymphoma is very rare, accounting for only 0.008% of cervical malignancies. (Sant et al., 2010) Although DLBCL patients often present with abnormal vaginal bleeding, it was not involved in this case. In this article, we present a rare case of primary cervical diffuse large B-cell lymphoma with urinary tract symptoms.
A 71-year-old woman who had been suffering from dysuria for two months came to our hospital. A pelvic examination revealed a 10 cm cervical mass, while HPV and squamous cell carcinoma (SCC) antigen tests were negative. The bulky cervical mass invaded the posterior wall of the uterus, vagina, superior rectum, bladder, and bilateral lower ureters, resulting in dysuria and dilatation of the upper ureter. Histopathological and immunohistochemical examination confirmed DLBCL and PET-CT suggested that it was stage IV. After two cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), the large lesions were eliminated. Unfortunately, the patient suffered an untimely death unrelated to her disease before the fourth cycle of R-CHOP could begin.
DLBCL of the cervix is a rare, but potentially curable disease if the diagnosis is made accurately, and doing so requires a high index of suspicion for cervical masses with an atypical presentation in which traditional diagnostic methods are equivocal. Obtaining adequate multilayered lesion biopsies containing both cervical epithelium and mesenchyme helps to avoid misdiagnoses. Histopathological biopsy and immunohistochemistry are the gold standards for diagnosis, and R-CHOP chemotherapy is an effective treatment.
弥漫性大B细胞淋巴瘤(DLBCL)是一种罕见疾病,粗年发病率为每10万人3.8例。此外,原发性宫颈淋巴瘤非常罕见,仅占宫颈恶性肿瘤的0.008%。(桑特等人,2010年)尽管DLBCL患者常出现异常阴道出血,但该病例未涉及此症状。在本文中,我们报告一例罕见的原发性宫颈弥漫性大B细胞淋巴瘤伴尿路症状的病例。
一名71岁女性,因排尿困难两个月前来我院就诊。盆腔检查发现宫颈有一个10厘米的肿块,而人乳头瘤病毒(HPV)和鳞状细胞癌(SCC)抗原检测均为阴性。巨大的宫颈肿块侵犯了子宫后壁、阴道、直肠上段、膀胱和双侧输尿管下段,导致排尿困难和上尿路扩张。组织病理学和免疫组化检查确诊为DLBCL,正电子发射断层扫描-计算机断层扫描(PET-CT)提示为IV期。经过两个周期的利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松(R-CHOP)治疗后,大的病灶消失。不幸的是,在第四个周期的R-CHOP治疗开始前,患者意外死亡,与疾病无关。
宫颈DLBCL是一种罕见但如果诊断准确可能治愈的疾病,对于具有非典型表现且传统诊断方法不明确的宫颈肿块,需要高度怀疑才能做到这一点。获取包含宫颈上皮和间充质的足够多层病变活检有助于避免误诊。组织病理学活检和免疫组化是诊断的金标准,R-CHOP化疗是一种有效的治疗方法。